CIMAher

A A A

CIMAB S.A., 206 Street, No. 1926, ATABEY, Playa, Ciudad de La Habana, CUBA
Tel.: (53 7) 2725162, 2725163, 2715057
Fax: (53 7) 2733509
Email: cimab@cim.sld.cu

CIMAher (nimotuzumab) is a humanized monoclonal antibody that recognized the Epidermal Growth Factor receptor with a high affinity for the Cancer treatment.

CIMAher for PROFESSIONALS

CIMAher for PATIENTS

Product description

Therapeutic indications

Sanitary Registrations

Clinical Studies

Publications

Warning about possible adverse reactions
Contact information by countries
Links to usefull information

What is CIMAher?
CIMAher (nimotuzumab) is a humanized monoclonal antibody that reacts with the Epidermal Growth Factor receptor (EGFR) with a high affinity, blocking the interaction between the Epidermal Growth Factor (EGF) and its receptor.
◄ Image of a monoclonal antibody.
How works CIMAher?
The EGF and their receptor play a very important role in cells growth in the organism, in ... (Read more)

News

Nuevas publicaciones del nimo

Lung Cancer y Cancer Chemotherapy and Pharmacology han publicado recientemente los resultados de dos estudios clínicos de prueba ... (Read more)

New papers

New papers of nimotuzumab results presented in ASCO 2010. ... (Read more)

List all news

Professionals's opinion

Dra. Patricia Piedra Sierra - CIMAB S.A. Medical Manager

CIMAher (nimotuzumab) is a biological product, very well tolerated and with clear evidence of antitumor activity in patients with advanced tumors of h ... (Read more)

See all opinions